Charlotte Pahl
Director/Miembro de la Junta en Reponex Pharmaceuticals A/S .
Fortuna: 157 152 $ al 30/06/2024
Cargos activos de Charlotte Pahl
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Reponex Pharmaceuticals A/S
 Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Director/Miembro de la Junta | - | - |
Historial de carrera de Charlotte Pahl
Estadísticas
Internacional
| Dinamarca | 2 |
Operativa
| Director/Board Member | 1 |
Sectorial
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Reponex Pharmaceuticals A/S
Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Health Technology |
- Bolsa de valores
- Insiders
- Charlotte Pahl
- Experiencia
